Navigation Links
QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations

VALENCIA, Calif. and GERMANTOWN, Md., Dec. 15 /PRNewswire-FirstCall/ -- QIAGEN (Nasdaq: QGEN, Frankfurt: QIA), which has its global headquarters in the Netherlands and United States offices in five locations, brought on board its 3,000th employee this month. Company officers hailed this growth as a symbol of the biotech company's continued strong performance and outlook, and pledged to sustain its investment both in the U.S. and abroad. QIAGEN is the leading provider of sample and assay technologies, which are designed to unlock the secrets of DNA to help scientists understand the building blocks of life, detect biological agents that can cause disease and facilitate law enforcement. The company's 3,000th employee joined QIAGEN's facility in Valencia, Calif.

"The U.S. is the largest market for QIAGEN and key to our global success," says Dr. Hans Peter Fatscher, Chairman of the Americas Management Council. "It accounts for 52 percent of QIAGEN's total revenues and a third of our global workforce. In North America -- particularly at our U.S. headquarters in Montgomery County, Maryland -- we have benefited from a well-trained workforce, access to the latest technologies and other favorable conditions that help us grow the entire company. There is no other market that allows us to so rapidly turn innovation into commercial success."

QIAGEN entered the U.S. market in 1988, when it opened a one-person office in Los Angeles. Today, the company employs close to 1,000 employees in five U.S. locations, generating annual sales of approximately $500 million. Over the past 20 years, QIAGEN has invested more than $2 billion in the U.S., including its $1.6 billion merger with Gaithersburg, MD based Digene Corp. in 2007.

According to Douglas Liu, Vice President of Global Operations and member of the company's Global Executive Committee, economic slowdowns are less likely to affect molecular diagnostics, biotech industry, life science research and QIAGEN than other sectors and companies. "Public and private budgets in the healthcare industry are more robust than in other sectors. And due to QIAGEN's prominence in multiple laboratory applications in the U.S. and globally, our business is expected to continue growing," says Liu. QIAGEN technologies are used to prepare and analyze biologic samples, such as blood and tissue and are regarded as standards in academic research, pharmaceutical research, forensic labs, molecular diagnostics and other research applications. Last month, QIAGEN announced strong quarterly results, allowing the company to raise its earnings guidance for the second time this year. The U.S. significantly contributed to this development, as the fastest growing global market segment for QIAGEN, with a growth rate of almost 30 percent.

"QIAGEN is one of Montgomery County's great success stories, and its continued growth as a whole and, in particular, here at its U.S. headquarters in the county since 2002, illustrates the company's strength and position as a leading global biotech company," said Dr. Pradeep Ganguly, Director, Montgomery County Department of Economic Development. "QIAGEN is one of the largest biotechnology companies in Montgomery County and contributes significantly to the county's position as a global biotech industry leader."

Montgomery County, Maryland is home to more than 200 life sciences firms, 19 federal agencies, 30 federal labs, more than 60 international companies and more than 40,000 life science professionals working throughout the private sector, federal laboratories, foundations and academia.

According to the Maryland Department of Business and Economic Development, foreign investment in the biotech sector -- one of the fastest-growing business segments -- accounts for more than 105,000 jobs in Maryland -- or 5.5 percent of the state's private sector employment. QIAGEN's commitment is further evidence of Maryland's position as one of the world's leading locations for biotechnology innovation. Under Maryland Governor Martin O'Malley's BIO 2020 initiative, Maryland intends to invest another $1.3 billion in the state's bioscience industry -- the largest per capita investment in the biosciences made by any state in the country -- over the next 10 years to attract and further grow foreign and domestic biotech companies in the region.


QIAGEN N.V., a Netherlands holding company, is the leadingglobalprovider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables.The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 3,000 people in over 30 locations worldwide. Further information about QIAGEN can be found at

Statements contained in this release that are not historical facts are forward-looking statements, including statements about our products, markets, strategy and operating results. Such statements are based on current expectations that involve risks and uncertainties including, but not limited to, those associated with: management of growth and international operations (including currency fluctuations and logistics), variability of our operating results, commercial development of our markets (including applied testing, clinical and academic research, proteomics, women's health/HPV testing and molecular diagnostics), our relationships with customers, suppliers and strategic partners, competition, changes in technology, fluctuations in demand, regulatory requirements, identifying, developing and producing integrated products differentiated from our competitors' products, market acceptance of our products, and integration of acquired technologies and businesses. For further information, refer to our filings with the SEC, including our latest Form 20-F. Information in this release is as of the date of the release, and we undertake no duty to update this information unless required by law.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SciQuest Announces Strategic Alliance with QIAGEN
2. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Second Quarter 2008 Financial Results Call Set for August 5
3. Webcast Alert: QIAGEN N.V. Announces First Quarter 2008 Earnings Conference Call
4. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Fourth Quarter and Year End 2007 Earnings and 2008 Guidance Conference Call on the Web
5. Histogen Welcomes Dr. Hyma Gollamudi as Chief Business Officer
6. Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory
7. South Africas Minister of Minerals and Energy Welcomes Denham Capital Investment in BioTherm Energy to Develop Power Generation Business
8. Vineland Welcomes Dr. Isabelle Lesschaeve as Research Chair, Sensory and Consumer Sciences
9. Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
10. Vineland Welcomes Dr. Daryl Somers as Research Chair, Molecular Breeding and Biotechnology
11. Spring Point Project Welcomes Second Generation Medical-Grade Piglets
Post Your Comments:
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... ... 23, 2016 , ... Velocity Products, a division of Morris ... optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, ... several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity ...
(Date:6/23/2016)... PUNE, India , June 23, 2016 /PRNewswire/ ... culture media market research report to its pharmaceuticals ... company profiles, product details and much more. ... market spread across 151 pages, profiling 15 companies ... now available at . ...
Breaking Biology Technology:
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):